复旦张江(01349.HK) 公布,经审慎研究,决定自5月1日起按照各省份对于未中选产品的规则和要求,陆续调整、梯度降低药品里葆多的市场零售价格,相比此前中标价格降价幅度不低于35%。因此,预计对该药物今年第二季度及后续的销售收入产生不利影响,并导致该药物2025年度销售收入下降。
集团纳米技术平台抗肿瘤药物盐酸多柔比星脂质体注射液(商标名:里葆多)于2009年8月上市销售,2024年首次获纳入国家集采目录。2024年度销售收入约2.1亿人民币,占集团全年销售收入的29%。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-30 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.